Skip to main content
EXEL
NASDAQ Life Sciences

Farallon Sells ~2.6M Exelixis Shares Into Rally, Drops Below 5% Stake

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$71.74
Mkt Cap
$17.505B
52W Low
$39.71
52W High
$73.69
52W Position info
81% above low
Off High info
2.6% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

EXEL sits 81% above its 52-week low of $39.71 on elevated volume (2.0× avg).

Summary

Farallon Capital cut its Exelixis stake to 4.9% from 5.6%, selling about 2.6 million shares in October and early November at $60.96-$72.60 — largely into the stock's run to 52-week highs.


Key Events · Ownership and Investor Activity · EXEL

  • Farallon Drops Below 5% Threshold

    Farallon Capital reported 12,017,906 shares, or 4.9% of the 244,010,895 shares outstanding as of October 19, 2026, and ceased to be a beneficial owner of more than 5% on November 6, 2026.

  • ~2.6M Shares Sold in 60 Days

    Exhibit 1.D shows sales from October 14 to November 6, 2026, including 568,000 shares at $69.84 on October 30 and 255,661 at $72.60 on November 3, versus purchases in September at $57.07-$60.11.

  • Selling Into 52-Week Highs

    Sale prices of $60.96-$72.60 compare with a 52-week high of $73.69, indicating profit-taking into strength rather than distress selling.

  • Prior Filing Showed 5.6% and Buying

    The August 14, 2026 Schedule 13D/A reported a 5.6% stake with net buying of about 1 million shares; the position has since been reduced.


Analysis · EXEL · Life Sciences

A long-time large holder, Farallon Capital, sold roughly 2.6 million shares between October 14 and November 6 and now holds 12.0 million shares, or 4.9% — below the 5% threshold that requires 13D reporting. The sales came at $60.96 to $72.60, i.e. into a stock trading near its 52-week high of $73.69, and reverse the buying Farallon did in September at $57-$60. This is a financial investor taking profits, not an operational signal, but it removes a large holder's support and puts roughly 12 million shares of remaining overhang in play. Note the August 14 filing showed Farallon at 5.6% and net buying; the direction has now flipped.

How filings like this one have moved

In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, EXEL was trading at $71.74 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $17.5B. The 52-week trading range was $39.71 to $73.69. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

EXEL - Latest Insights

EXEL
Oct 29, 2026, 4:16 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $66.35
Real-time Price: $71.74 info
Change: +$5.39 (+8%) info
Market Cap: $17.505B info
EXEL
Oct 29, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $66.35
Real-time Price: $71.74 info
Change: +$5.39 (+8%) info
Market Cap: $17.505B info
EXEL
Oct 29, 2026, 4:05 PM EDT
Source: BusinessWire
Importance Score:
8
Price at Filing: $66.34
Real-time Price: $71.74 info
Change: +$5.40 (+8%) info
Market Cap: $17.505B info
EXEL
Sep 11, 2026, 7:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $57.40
Real-time Price: $71.74 info
Change: +$14.34 (+25%) info
Market Cap: $17.505B info
EXEL
Aug 31, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $54.64
Real-time Price: $71.74 info
Change: +$17.10 (+31%) info
Market Cap: $17.505B info